OmniAb, Inc. offers a technology platform built around transgenic animals that produce diverse repertoires of fully human antibodies for therapeutic development. Pharmaceutical partners access the platform to discover and optimize antibody candidates through integrated screening and engineering tools. The model relies on licensing and collaboration agreements with drug developers worldwide.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 4.2 | — | -18.2 | — |
| Q2 2025 | 3.9 | — | -15.9 | — |
| Q3 2025 | 2.2 | — | -16.5 | — |
| Q4 2025 | 8.4 | — | -14.2 | — |
| Q1 2026 | 14.4 | 247.3% | -7.7 | — |
| Q2 2026 | 13.4 | 244.2% | -5.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Red River Bancshares, Inc. (RRBI), Canadian Solar Inc. (CSIQ), Park-Ohio Holdings Corp. (PKOH), Eos Energy Enterprises, Inc. (EOSE), Pharming Group N.V. (PHAR), Immix Biopharma, Inc. (IMMX)